论文信息 - A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer - 字舞流文

A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer

T. Onaka | Fumie Iwai | Aiko Kato-Ogura | Yasuyuki Otsuka | Akihito Yonezawa

[1] K. Mori,et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia , 2017, Investigational New Drugs.